Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
JTO Clinical and Research Reports|May 2, 2022
Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in PracticeAnjali Saqi, Kevin O Leslie, Andre L Moreira, et al.JTO Clinical and Research Reports|August 11, 2025
Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed AnalysisJay M Lee, Alessandro Brunelli, Amy L Cummings, et al.Urology|February 25, 2003
Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinomaKen-Ryu Han, Allan J Pantuck, Matthew H T Bui, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2011
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinibLinda Mileshkin, Rodney J Hicks, Brett G M Hughes, et al.Lung Cancer (Amsterdam, Netherlands)|July 27, 2012
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II ConsortiumNicholas P Campbell, Rangesh Kunnavakkam, Natasha Leighl, et al.Oncotarget|July 10, 2024
Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinomaAlexandra Jackovich, Barbara J Gitlitz, Justin Wayne Wong Tiu-Lim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2011
A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trialBarbara J Gitlitz, Denice D Tsao-Wei, Susan Groshen, et al.Frontiers in Oncology|March 28, 2019
Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303)Karen L Reckamp, Paul H Frankel, Nora Ruel, et al.JTO Clinical and Research Reports|September 30, 2021
The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung CancerBarbara J Gitlitz, Silvia Novello, Tiziana Vavalà, et al.Cancer Chemotherapy and Pharmacology|August 22, 2018
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumorsStephen V Liu, Susan G Groshen, Karen Kelly, et al.Pageof 5